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Abstract
Background: Nitric oxide (NO) synthesized by endothelial nitric oxide synthase (eNOS) plays an
important role in regulation of endothelial function and in the control of blood pressure. However,
the results from some studies on the association between three clinically relevant eNOS gene
polymorphisms (G894T, T786C and intron 4b/a) and essential hypertension are unclear. We
designed a case-control study to evaluate the influence of eNOS polymorphisms on target organ
damage in 127 hypertensives and 67 normotensives. Clinical evaluation, biochemical parameters,
Urinary Albumin Excretion (UAE) and echocardiogram were performed to characterize target
organ damage. eNOS polymorphism were recognized by PCR method.
Results: The distribution of eNOS genotypes was similar in hypertensives and normotensives but
4aa was present in the 2.5% of hypertensives and completely absent in normotensives. Subjects
with 4bb, G894T, and T786C genotypes showed an increased prevalence of target organ damage.
Moreover prevalence of G894T and introne 4 variants was significantly higher in hypertensives than
in normotensives both with cardiovascular damage. Logistic regression analysis didn't show any
association between eNOS polymorphisms, Body Mass Index (BMI), hypertension, gender and
cardiovascular damage. Only the age (OR 1.11; IC 95% 1.06–1.18) was predictive of cardiovascular
damage in our population.
Conclusion:  Our results seem to indicate a lack of association with eNOS variants and
cardiovascular damage onset.
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Background
Hypertension is a multifactorial disease involving both
environmental and genetic components. Clinical and
experimental studies suggest that an alteration in nitric
oxide (NO) metabolism may be a contributing factor in
the pathogenesis of hypertension. Thus, abnormalities in
the activity of the enzyme endothelial NO synthase
(eNOS) that synthesizes NO in endothelial cells may lead
to NO deficiency with severe consequences. In fact, NO
plays a pivotal role in the preservation of the endothelium
homeostasis, regulation of vasomotor tone and control of
blood pressure [1]
The gene encoding eNOS is located on chromosome 7
(7q35-q36) and contains 26 exons with an entire length
of 21 kb. Disruption of eNOS gene leads to hypertension
in mice [2] and inhibition of eNOS elevates blood pres-
sure in healthy humans [3]. Furthermore, NO production
is diminished in patients with essential hypertension
(EH), under basal conditions [4]. On this important evi-
dence the eNOS gene has been investigated as a putative
candidate gene for EH. G894T, T786C and intron 4 (4b/
a) are the most clinically relevant polymorphisms in the
eNOS gene that have been described. However, the results
of most association studies were inconsistent among dif-
ferent ethnicities and even among different populations
from the same ethnicity [5-7].
The single nucleotide polymorphism (SNP), G894T
within exon 7, resulting in a replacement of glutamic acid
by aspartic acid at codon 298 (Glu298Asp), is the most
highlighted variant whose association with hypertension
is still controversial. In particular, the G894T was found to
be associated with increased risk of hypertension in Cau-
casian [8] and Japanese [9], but in another two studies it
was not (neither in Caucasian nor in Japanese) [10,11].
Recently, a functional 27-bp variable number of tandem
repeats (VNTR) in intron 4 (intron4b/a) of eNOS gene has
been reported to coordinate with another SNP at the pro-
moter region (T786C). It regulates transcription efficiency
in a haplotype-specific way which is modifiable by ciga-
rette smoking [12]. Although no association has been
reported between intron4b/a, T-786C and hypertension,
most association studies did not examine the combining
effect of these two polymorphisms on the development of
hypertension [9,13,14]. Nonetheless, it is generally
accepted that these variants can modify the NO produc-
tion and may predispose non only to hypertension [5] but
also to ischemic heart disease [15] or renal damage [16].
The aim of the present study was to investigate the rela-
tionship between eNOS polymorphisms, G894T, T786C
and intron4b/a and cardiovascular damage in hyperten-
sive patients. The main goal of the study was to evaluate if
eNOS polymorphisms might be associated to cardiovas-
cular damage in these subjects.
Methods
We enrolled 127 subjects aged from 40 to 55 years,
screened at the Department of Internal Medicine, Univer-
sity of Palermo (Italy). Subjects were considered to be
hypertensive if their systolic/diastolic blood pressure was
≥ 140/90 mm Hg, confirmed in three following measure-
ments; or ≥ 130/85 mm Hg if diabetic; or if the subjects
were on hypertensive therapy. A mercury sphygmoma-
nometer was used with cuff of suitable dimensions in all
the obese subjects. The degree of obesity was assessed
through the Body Mass Index (BMI) and the distribution
of the fat, central or peripheral, through the analysis of the
waist/hip ratio (WHR) [17]. Family history for early cardi-
ovascular events were analyzed as previously reported
[18].
We also recruited 67 normotensive controls aged 40 to 55
years. Written informed consent was obtained from all the
subjects enrolled in this study and this study was
approved by Ethic Committee of our Institution.
Exclusion criteria included secondary hypertension, endo-
crinal disease, cardiovascular diseases (defined as myocar-
dial infarction and recent stroke within previous 6
months, heart failure) severe chronic renal failure, alco-
holism and psychiatric problems. All patients were subse-
quently divided into two groups according to the presence
of target organ damage such as left ventricular hypertro-
phy, carotid atherosclerosis, microalbuminuria, retinopa-
thy and diabetes mellitus. At the time of enrolment, Blood
Urea Nitrogen (BUN), creatinine and clearance, glycae-
mia, electrolytes (serum sodium, potassium, chloride),
were measured for each patient by routine laboratory
methods. Genotyping was performed by investigators
blinded to clinical status.
Genotype determination
Genomic DNA was prepared from blood leukocytes by
established methods (kit Promega). The presence of the T-
786C and G894T eNOS polymorphisms was examined by
PCR-RFLP analysis. The introne 4 polymorphism was
investigated by voltage gradient gel electrophoresis
(VGGE). To ensure objectivity, DNA analysis was blinded
to clinical status of the patients.
A set of primers was designed to amplify a 206 bp frag-
ment including the missense Glu298Asp variant (G894T
polymorphism) [5'-CAT GAG GCT CAG CCC CAG-
3'(foward) and 5'-AGT CAA TCC CTT TGG TGC TCA C-3'
(reverse)]. The PCR fragment digested overnight at 37°C
with the MboI restriction enzyme was separated by electro-
phoresis on 2% agarosium gel and visualized by etidiumImmunity & Ageing 2008, 5:4 http://www.immunityageing.com/content/5/1/4
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bromide staining. In the presence of a T nucleotide at
position 894 corresponding to Asp 298, the 206 bp PCR
product was cleaved into two fragments of 119 and 87 bp;
whereas the presence of a G removed the restriction site
recovering a single fragment of 206 bp. The T-C transition
at position 786 in the 5' flanking region of eNOS gene was
investigated by PCR using 5'-ATG CTC CCA CCA GGG
CAT CA-3' (foward) and 5'-GTC CTT GAG TCT GAC ATT
AGG G-3' (reverse), as primers. The PCR fragment (236 bp
long) was digested with the NgOAIV restriction enzyme
overnight at 37°C. The wild type (786T) has no cleavage
site, whereas in the presence of 786C the PCR product is
cleaved into two fragments of 203 and 33 bp. The 27-bp
repeat polymorphism in introne 4 was investigated by 5'-
AGG CCC TAT GGT AGT GCC TTT-3'(forward) and 5'-
TGC TCC TGC TAC TGA CAG CA-3'(reverse) as primers.
Two fragments of different length were obtained: one of
220 bp corresponding to the allele b with five repetitions
of 27 couples of bases and one of 193 bp (allele a) with
four repetitions. Voltage gradient gel electrophoresis
(VGGE) discriminate with a good resolution the two frag-
ments on a 2% agarosium gel. In fact, 4bb-carriers pro-
duce a visible single band of 220 bp; 4ba- carriers two
bands, one for the allele b (220 bp) and one for the allele
a (193 bp); 4aa-carriers a single band of 193 bp.
Albumin Excretion Rate (AER)
To eliminate the intra-individual day-to-day variability of
AER, three consecutive 24 h urine collections were used.
In addition, to assess the completeness of a 24 h urine col-
lection, measurements of urinary rate of clearance of cre-
atinine were evaluated. AER was measured by
Table 2: Prevalence of the clinical characteristics and the comorbidities in hypertensives and normotensives
Normotensives n.67 Hypertensives n.127 p <
Family history for early CV events (%) 0.0 8.6 0.04
Family history for not early CV events (%) 36.8 52.4 n.s.
Family history for diabetes mellitus (%) 13.2 15.2 n.s.
Diabetes mellitus (%) 3.0 5.5 n.s.
Retinopathy (%) 23.3 68.4 0.001
LVH (%) 13.9 28.7 0.04
Carotid Atherosclerosis (%) 20.6 51.3 0.001
Normal weight (%) 21.6 10.2 n.s.
Overweight (%) 46.0 43.9 n.s.
Obesity (%) 32.4 45.9
Central obesity (%) 71.4 80.0 n.s.
CV = cardiovascular; LVH: left ventricular mass.
Table 1: Clinical and biochemical characteristics of the studied population
Normotensives Hypertensives p <
Patients (n°) 67 127
Women (%) 58 56
Men (%) 42 44
Age (years) 48.5 (40.0–55.0) 50.0 (44.0–57.0) 0.002
Weight (Kg) 77.4 (66.0–85.0) 80.0 (70.0–90.5) n.s.
High(cm) 1.7 (1.6–1.7) 1.7 (1.6–1.7) n.s.
BMI (Kg/m2) 27.1 (25.5–31.2) 29.3 (26.8–32.4) n.s.
WHR 0.9 (0.9–1.0) 0.9 (0.9–1.0) n.s.
SBP (mmHg) 127.5 (115.0–130.0) 140.0 (130.0–150.0) 0.001
DBP(mmHg) 80.0 (70.0–85.0) 90.0 (80.0–95.0) 0.001
MBP(mmHg) 94.2 (86.7–100.0) 106.7 (98.8–113.3) 0.001
BUN (mg/dl) 36.0 (31.0–39.0) 37.5 (33.3–44.0) n.s.
Creatinine (mg/dl) 0.8 (0.7–0.9) 0.8 (0.7–0.9) n.s.
Clearance (ml/min) 126.0 (100.3–153.0) 112.0 (88.1–140.0) n.s.
AER(mg/24 h) 53.4 (21.3–150.5) 73.6 (44.4–122.0) 0.05
LVM (g) 145.8 (118.2–176.8) 161.1 (143.4–192.0) 0.007
LVM/h2,7 35.7(31.7–43.0) 41.4 (36.0–49.5) 0.004
Insulin (μUI/ml) 8.0 (4.5–12.4) 10.5 (8.0–15.0) n.s.
BMI: body mass index; WHR: waist/hip ratio; PAS: systolic artery pressure; PAD; diastolic artery pressure; PAM: media artery pressure; BUN: 
blood urea nitrogen; AER: albumin excretion rate; LVM: left ventricular mass; LVM/h2.7: left ventricular mass/high2.7.
Data are presented as median (lower-upper quartiles)Immunity & Ageing 2008, 5:4 http://www.immunityageing.com/content/5/1/4
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immunonephelometric assay (Bohering Institute; limit of
detection, 0.1 mg/dl; Inter-assay coefficient 3.5%).
Patients were defined as microalbuminuric if the level of
AER was ≥ 20 and < 300 mg/24 h.
Echocardiographic Measurements
All patients underwent an echocardiography examination
M and B-mode, by a computerized echocardiography
(ESAOTE, Italy) for the determination of the following
parameters: 1) left ventricular telediastolic internal diam-
eter (LVIDd), 2) interventricular septum (IVSTd), and 3)
posterior wall thickness (PWTd). The Penn convention
was used to calculate left ventricular mass (LVM). LVM
was normalized for height to the 2.7 power [19]. Accord-
ingly, all the hypertensives with LVM/h2.7 ≥ 50 g/m2.7 for
men and ≥ 47 g/m2.7 for women were considered to have
left ventricular hypertrophy (LVH). The relative wall thick-
ness (RWT) [(PWTd/LVIDd)x2] was also calculated. Ejec-
tion fraction from left ventricular end-diastolic and end-
systolic volumes was measured from the apical four
chamber view, using the ellipsoidal single-plane algo-
rithm. Mean ejection fraction was automatically calcu-
lated by the echocardiographic processing system. In our
laboratory the ejection fraction calculated over five con-
secutive beats permitted optimal reproducibility and
accuracy.
LV relaxation and filling were evaluated by pulsed-wave
Doppler interrogation of the LV inflow tract from the api-
cal four-chamber view, with the sample volume placed at
the tips of the mitral valve. After a stable signal of the
transmitral flow velocity was obtained, the Doppler cur-
sor was moved toward the LV outflow tract in the apical
five-chamber view for recording both mitral and aortic
signals, including the closing click of the aortic valve and
the opening click of the mitral valve. Doppler signals were
recorded at high speed (80–120 mm/s) with the subjects
in held expiration. An average of five beats was used for
analysis.
Isovolumic relaxation time (IVRT) was calculated as the
time from the closure click of the aortic valve to the open-
ing click of the mitral valve. When either the closing or
opening click was not identified, the time from the end of
Table 3: Genotype frequency distribution of the three polymorphisms
Normotensives n. 67 Hypertensives n. 127 p <
G894T GG (19/67) 28% (45/127) 35.4% n.s.
GT (41/67) 61% (70/127) 55.1% n.s.
TT (7/67) 11% (12/127) 9.5% n.s.
GT+TT 72% 61.6% n.s.
Alleles N°134 N°256
G (79/134) 59% (160/256) 63% n.s.
T (55/134) 41% (94/256) 37% n.s.
Normotensives n. 38 Hypertensives n. 107 p <
T786C TT (8/38) 21% (25/107) 23% n.s.
TC (19/38) 50% (51/107) 48% n.s.
CC (11/38) 29% (31/107) 29% n.s.
TC+CC 79% 78% n.s.
Alleles N°76 N°214
T (35/76) 46% (101/214) 47% n.s.
C (41/76)54% (113/214) 53% n.s.
Normotensives n. 31 Hypertensives n. 119 p <
introne 4 bb (24/31) 77% (86/119) 72.5% n.s.
ba (7/31) 23% (30/119) 25% n.s.
aa (0/31) 0% (3/119) 2.5% 0.005
ab+aa 23% 27.5% n.s.
Alleles N°62 N°238
b (55/62) 89% (202/238) 85% n.s.
a (7/62) 11% (36/238) 15% n.s.Immunity & Ageing 2008, 5:4 http://www.immunityageing.com/content/5/1/4
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the aortic flow to the onset of mitral flow from the contin-
uous wave interrogation of the LV inflow-outflow tract
was used. Peak early transmitral flow velocity (E), peak
late transmitral flow velocity (A), and the deceleration
time of E velocity (DTE) were measured at the tips of
mitral leaflets at the maximum amplitude of E velocity.
DTE was measured as the time from peak E velocity to the
time when E wave descent intercepts the zero line.
Carotid evaluation
Arterial carotid wall was evaluated with high resolution B-
mode ultrasonography with an ultrasound device
(TOSHIBA SSA 270HG) equipped with a linear (7.5 MHz)
transducer. Subjects were examined in the supine position
with slight hyperextension of the neck on a longitudinal
two-dimensional ultrasound image of carotid, the near
and far arterial wall are displayed as two bright white lines
separated by hypoechogenic space. The distance between
the leading edge of the first bright line on the far wall
(lume-intima interface) and the leading edge of the sec-
ond bright line (media-adventitia interface) indicates the
intima-media thickness of the far wall. A 1.5 cm segment
of the common carotid artery (immediately caudal to the
carotid bulb) and the proximal 1.5 cm segment of the
internal carotid artery was considered. Within each seg-
ment, three measurements of IMT were taken ad wall
thickness was not measured at the site of a discrete plaque.
Statistical analysis
Data are reported as median (lower-upper quartiles)
Comparisons of continuous variables were performed
with the Mann-Whitney non parametric test. Frequencies
were calculated using the comparison of two independent
binomial proportions according to Armitage and Berry
[20]. The Fisher test was used for the analysis of tables of
contingency. Moreover, to study the possible associations
among the examined variables and the cardiovascular
damage, a model of logistic regression was built according
to Hosmer and Lemeshow [21] for the calculation of
adjusted odds ratios (OR) and intervals of confidence
(IC). A p values <0.05 was considered statistically signifi-
cant.
Results
The clinical characteristics of the studied population was
reported in table 1. Hypertensive and normotensive
groups were homogeneous for sex, BMI, WHR. Age (p <
0.002), systolic (p<0.001); diastolic (p<0.001); mean
blood pressure (p<0.001), left ventricular mass indexed
for height^2.7 (p < 0.004) and AER (p < 0.05) were signif-
icantly higher in hypertensives than normotensives. The
prevalence of the clinical characteristics and the comor-
bidities in the hypertensives and normotensives was
reported in table 2. In particular, a significant higher prev-
alence of family history for early cardiovascular events (p
< 0.04), retinopathy (p < 0.001) left ventricular hypertro-
phy (p < 0.04) and carotid atherosclerosis (p < 0.001) was
found in hypertensives than normotensives. The genotype
frequency distribution of the three polymorphisms was
reported in table 3. Out of 194 subjects, the G894T,
T786C and introne 4 genotypes were determined for 194,
145 and 150 patients, respectively. Genotype frequency
distribution is in accordance with the Hardy-Weinberg
equilibrium and it is similar in the two groups. Only 4aa
genotype distribution was significantly (p < 0.005) higher
in hypertensives than normotensives.
T894, C786 and 4a were considered rare alleles and their
relationship with study variables was analysed by domi-
nant or recessive models, presenting only the former (GG
versus GT+TT; TT versus TC+CC; bb versus ab+aa) because
the results did not differ. Accordingly, in table 4 the rela-
tionship of cardiovascular damage and genotypes in
hypertensives and normotensives was reported. The sub-
group with cardiovascular damage was characterized by a
greater prevalence (p < 0.001) of GT+TT, TC+CC genotype
and homozygosis for the allele b (table 4). Moreover, to
appraise the role of hypertension in the association
among eNOS variants and cardiovascular damage, we
compared the prevalence of eNOS genotype in the hyper-
tensives and normotensives both with cardiovascular
damage (table 5). Hypertensives with cardiovascular dam-
age were characterized by a greater prevalence of G894T
polymorphism (p < 0.001) and introne 4 mutations (p <
0.05) than normotensives.
Logistic regression
We built a model of multiple logistic regression that
included, among the independent variables, the presence
or the absence of hypertension, BMI, age, sex and the het-
erozygous or homozygous genotypes The aim was to eval-
uate the possible association between the presence of
cardiovascular damage and a determined eNOS genotype.
From the analysis of the logistic regression, according to
Table 4: Prevalence of cardiovascular damage according to 
genotype in all subjects (hypertensives and normotensives 
subjects)
G894T n. 104 % p <
GG 38 36.5 0.001
GT+TT 66 63.5
T786C n.90
TT 19 21.1 0.001
TC+CC 71 78.9
Introne 4 n.96
bb 72 75 0.001
ab+aa 24 25Immunity & Ageing 2008, 5:4 http://www.immunityageing.com/content/5/1/4
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the model, only the age was associated to the presence of
cardiovascular damage (OR 1.11; IC 95% 1.06–1.18).
Discussion
Despite several clinical and experimental studies indicate
a relevant role in the alteration of NO metabolism in the
occurrence and severity of hypertension, no univocal date
was reported on the influence of NO Synthase polymor-
phism and hypertension and its sequelae [5]. To our
knowledge, this is the first study that has been designed to
investigate the influence of G894T, T786C and intron4b/
a eNOS polymorphisms on cardiovascular damage in
hypertensive subjects. It seems to indicate the following
data:
-a) the distribution of the genotypes G894T and T786C is
similar in hypertensives and normotensives, whereas the
homozygous condition for the allele a of the introne 4
(4aa) is present in the 2.5% of the hypertensives, and it is
completely absent in the normotensives;
-b) the subjects with cardiovascular damage were charac-
terized by an increased prevalence of 4bb, 894 (GT+TT)
and 786 (TC+CC) eNOS genotypes;
-c) a significant higher prevalence of G894T and introne 4
variants was found in hypertensives than normotensives
with cardiovascular damage. In our opinion, this associa-
tion doesn't reflect unknown differences in population
ancestry between the case-control groups. We consider the
probability of false positive inference attributable to pop-
ulation stratification rather small because the hyperten-
sive and control subjects were recruited from an ethnically
homogeneous population with no indication of a signifi-
cant amount of a recent genetic admixture.
Although these data might suggest an association between
eNOS polymorphisms and cardiovascular damage, logis-
tic regression analysis indicates that only the age may be
significantly associated with the cardiovascular damage in
our population. Although few studies have so far
addressed a similar issue, and all in clinical setting differ-
ent from ours, this finding is consistent with results of the
meta-analysis of Zintzaras et al [5] who point out that,
despite there is an elevated genetic contribution in the
control of arterial hypertension, complex mechanisms
and other factors (e.g. age and smoking) interact one with
another, and, in the long period, are likely to hide the real
role of eventual genetic variations. In particular, a low sta-
tistical power might explain the low-entity association
because our sample was empowered by its size to discrim-
inate only allelic odds ratio not lower than 2. Moreover
even though genetic linkage studies take advantage by
focusing on relatively well-defined intermediate pheno-
types (i.e. left ventricular hypertrophy, retinopathy,
intima-media wall thickness etc....), the influence of mul-
tiple susceptibility genes with powerful environmental or
gene-gene interactions makes it difficult to exclude con-
founding by some unmeasured factors [22,23]. Finally,
the discrepancy by us observed among the possible pres-
ence of a greater prevalence of some genotypes in the
hypertensives with cardiovascular damage in comparison
to the normotensives and the results of the logistic regres-
sion emphasize some methodological biases in defining
Table 5: Prevalence of eNOS genotype in hypertensives and normotensives with cardiovascular damage
G894T Normotensives n.67 % Hypertensives n. 127 %
GG 5 7.5 33 26.0*
GT+TT 14 20.9 52 40.9#
T786C Normotensives n.38 % Hypertensives n.107 %
TT 2 5.3 17 15.9
TC+CC 14 36.8 57 53.2
Introne4 Normotensives n. 31 % Hypertensives n. 119 %
bb 10 32.3 62 52.1
ab+aa 3 9.7 21 17.6 §
* p < 0,001 vs normotensives
# p < 0,007 vs normotensives
§ p < 0,05 vs normotensivesPublish with BioMed Central    and   every 
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the role of genetic associations with a clinical condition,
like cardiovascular damage, notoriously in progress and
modifiable over the time. In our study this might be due
to age of subjects we have recruited. Accordingly, to eval-
uate if this is the case, perspective studies including young
hypertensive subjects and focusing on gene environment
interactions as well as haplotype analysis are necessary.
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